Analysis of the correlation between the expression of PPP2R3A gene and prognosis in patients with HBV-related hepatocellular carcinoma

Abstract

Abstract: Objective To investigate the expression level of protein phosphatase 2A regulatory subunit B alpha (PPP2R3A) gene in patients with Hepatitis B virus (HBV) related hepatocellular carcinoma and its relationship with prognosis. Methods Utilizing the immunohistochemical method, we analyzed the expression levels of PPP2R3A protein in 82 samples of HBV-related hepatocellular carcinoma and 21 cases of benign liver disease. Additionally, the RT-PCR technique was applied to quantify the mRNA levels. Results Our findings revealed that the PPP2R3A protein expression in liver cancer tissue(95.12%) was substantially elevated compared to its levels in pericancerous tissue(43.9%), with statistical significance (P<0.05). There was a notable correlation between the expression intensity of PPP2R3A protein and the AFP value of liver cancer patients, exhibiting statistical difference (P<0.05). RT-PCR analysis indicated that the median mRNA expression level of PPP2R3A in HCC tissues was 0.183 (0.008~0.667), which was significantly higher than that in adjacent tissues (0.098 (0.004~0.583) (Z=6.839, P<0.05). By analyzing the survival data of follow-up HCC patients, it was found that the median overall survival (OS) of patients in the PPP2R3A high expression group was 46.6 months, which was significantly different from that in the low expression group (82.9 months) (P<0.05). The median survival of RFS in patients PPP2R3A the high-expression group was 18.3 months, which was lower than that in the low-expression group (42.6 months) (P<0.05). The median survival of PFS in patients PPP2R3A the high-expression group was 15.9 months, which was lower than that in the low-expression group (34.4 months) (P<0.05). The median survival of DSS in patients PPP2R3A the high-expression group was 70.5 months, which was lower than that in the low-expression group (84.7 months) (P<0.05). Conclusion The high expression of PPP2R3A protein in HBV-related hepatocellular carcinomar tissue and serum is related to the clinicopathological characteristics of liver cancer, which may be related to the poor prognosis of liver cancer.

Key words: PPP2R3A, Hepatitis B related liver cancer, Survival period, Tumor prognosis

TIAN Yi-cheng, TANG Zu-xiong, RU Gan, WANG Qi, ZHAI Chun-tao. Analysis of the correlation between the expression of PPP2R3A gene and prognosis in patients with HBV-related hepatocellular carcinoma[J]. Chinese Hepatolgy, 2024, 29(8): 956-959.

References 17

[1]	Mahmood F, Xu R, Awan MUN, et al. HBV Vaccines: Advances and Development[J]. Vaccines (Basel),2023,11(12):1862.
[2]	Kar A, Samanta A, Mukherjee S, et al. The HBV web: An insight into molecular interactomes between the hepatitis B virus and its host en route to hepatocellular carcinoma[J]. J Med Virol, 2023,95(1):e28436.
[3]	You M, Gao Y, Fu J, et al. Epigenetic regulation of HBV-specific tumor-infiltrating T cells in HBV-related HCC[J]. Hepatology, 2023,78(3):943-958.
[4]	黄燕萍, 张琴, 孙明瑜. 慢性乙型肝炎相关性肝细胞癌的危险因素研究进展[J]. 肝脏,2023,28(01):124-127.
[5]	康娅, 马金鑫, 戴光荣. 慢性乙型肝炎相关肝癌风险评估模型的研究新进展[J]. 肝脏,2024,29(02):243-246.
[6]	Dzulko M, Pons M, Henke A, et al. The PP2A subunit PR130 is a key regulator of cell development and oncogenic transformation[J].Biochim Biophys Acta Rev Cancer, 2020,1874(2):188453.
[7]	Younossi ZM, Wong G, Anstee QM, et al. The Global Burden of Liver Disease[J].Clin Gastroenterol Hepatol, 2023,21(8):1978-1991.
[8]	Amin P, Awal S, Vigneron S, et al. PP2A-B55: substrates and regulators in the control of cellular functions[J]. Oncogen, 2022,41(1):1-14.
[9]	Ronk H, Rosenblum JS, Kung T, et al. Targeting PP2A for cancer therapeutic modulation[J]. Cancer Biol Med, 2022,19(10):1428-1439.
[10]	Qi Y, Li L, Wei Y, et al. PP2A as a potential therapeutic target for breast cancer: Current insights and future perspectives[J]. Biomed Pharmacother, 2024,173:116398.
[11]	Sangodkar J, Farrington C C, Mcclinch K, et al. All roads lead to PP2A: exploiting the therapeutic potential of thisphosphatase[J]. FEBS J,2016,283(6):1004-1024.
[12]	陈慧娟, 王培晓, 张庆. PPP2R3A 基因与肿瘤的相关性研究进展[J]. 浙江医学,2019,41(8):845-847.
[13]	Peris I, Romero-Murillo S, Vicente C, et al. Regulation and role of the PP2A-B56 holoenzyme family in cancer[J]. Biochim Biophys Acta Rev Cancer, 2023,1878(5):188953.
[14]	何佳佳, 王培晓, 矫宁, 等. PPP2R3A基因在乙肝相关性肝癌中的表达及临床意义[J]. 实用器官移植电子杂志,2021,9(01):50-55.
[15]	王仕模, 胡永浩, 李强. AFP 水平与原发性肝细胞癌手术患者预后的相关分析[J]. 中华肝胆外科杂志,2017,23(2):134-136.
[16]	Lin J, Lin W, Ye Y, et al. Kindlin-2 promotes hepatocellular carcinoma invasion and metastasis by increasing Wnt/β-cateninsignaling[J]. J Exp Clin Cancer Res, 2017, 36(1):134.
[17]	Jin X, Liu Y, Liu J, et al. The Overexpression of IQGAP1 and β-catenin is associated with tumor progression in hepatocellularcarcinoma in vitro and in vivo[J]. PLoS One,2015,10(8):e0133770.